Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2017 Feb 1;16(3):417–427. doi: 10.1158/1535-7163.MCT-16-0498

Figure 5. Evaluation of alternative dosing schedules for selinexor and anti-PD-1.

Figure 5

Animals were injected subcutaneously with B16F10 on day 0 and were treated twice per week with selinexor and immune checkpoint blockade (or appropriate vehicle/isotype control) beginning when tumors became palpable using the alternative treatment schedules depicted in (a). (b) Growth curves of B16F10 tumors administered Selinexor (15 mg/kg) + anti-PD-1 on schedules 1 and 2. (c) Growth curves of B16F10 tumors administered Selinexor (10 mg/kg) + anti-PD-1 on schedules 3 and 4. (d) Growth curves of B16F10 tumors administered Selinexor (5 mg/kg) + anti-PD-1 on schedule 5. n=5 mice per group. Arrow indicates initiation of treatment.

Note: The vehicle/isotype control group in 5.b. and 5.c. consisted of the same animals. This line is present on both graphs for ease of reading. *, p=0.0332 between Schedule 1 and Schedule 2; **, p<0.0001 between Schedule 3 and Schedule 4.